SQZ Biotech to Present Preclinical Data on KRAS Tumor Targets & Next Generation SQZ eAPCs at the American Association for Can...
11 3월 2021 - 6:45AM
Business Wire
SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company
developing novel treatments for multiple therapeutic areas, today
announced that its team will present data on the next generation
SQZ™ APCs and the broader applicability of the APC platform at the
American Association for Cancer Research (AACR) 2021 Annual Meeting
being held virtually April 10-15, 2021. SQZ APC is a cell therapy
platform that aims to induce powerful antigen specific CD8+ T cell
responses. Two posters will highlight the additional functionality
of enhanced APCs (eAPCs) and potential patient population expansion
by leveraging multiple mRNA based cargos. A third poster describes
SQZ APCs in development for additional tumor types targeting both
G12D and G12V KRAS mutations.
SQZ eAPCs are designed to build on the power of the SQZ APC
platform to produce robust and specific CD8+ T cell activation
through efficient MHC-I antigen presentation. The platform
leverages the cargo flexibility of the Cell Squeeze® technology to
create next generation product candidates by delivering multiple
mRNA to potentially further enhance T cell stimulation. SQZ eAPCs
are being designed to incorporate immune-signaling that would
otherwise require combinations with additional immune-oncology
agents. In addition, the mRNA based antigen cargo is designed to
present a broader range of tumor antigen epitopes, aiming to
broaden the addressable patient population. The eAPC platform has
the potential to be applicable across future oncology and
infectious disease programs. Data examining these enhancement and
additional information will be shared in two posters at AACR.
SQZ is also applying its flexible technology to additional tumor
targets. KRAS G12D and G12V make up over half of all KRAS
mutations, with approximately 100,000 patients per year having KRAS
G12D or G12V mutated cancers in the United States. Leveraging the
flexibility of the Cell Squeeze® technology, SQZ APCs have elicited
specific KRAS G12D and G12V CD8+ T cells responses preclinically in
both animal models and in human cells. At AACR, we will show
preclinical data for SQZ APCs activating CD8+ T cells against KRas
G12D and KRas G12V when delivered individually or
simultaneously.
“The flexibility of the Cell Squeeze® technology enables us to
rapidly pursue new tumor types, such as those with KRAS mutations,
as well as to add diverse functionalities to our APCs,” commented
Howard Bernstein, MD, PhD, SQZ chief scientific officer. “Next
generation eAPCs are building on the strength of our SQZ APC’s
efficient and specific CD8 T cell activation. Further enhancing
cytokine and costimulatory signalling could be an innovative way
for us to provide the benefits of numerous immune-oncology
mechanism combinations into a single cell therapy. ”
SQZ eAPC Posters
Title: Enhancing Potency of Antigen Presenting Cells via
Signal 2/3 mRNA Engineering through Cell Squeeze® Technology
Abstract Number: 1525 Presenter: Emrah Ilker Ozay, PhD
Title: Cell Squeeze® Delivery of Antigen-Encoding mRNA
Enables Human PBMCs to Drive Antigen-Specific CD8+ T Cell Responses
for Diverse Clinical Applications Abstract Number: 2626
Presenter: Michael Maloney, PhD
SQZ APC KRAS Poster
Title: Peripheral Blood Mononuclear Cells Engineered Via
Microfluidic Cell Squeeze® Technology to Generate APCs that Drive
Mutant-KRas-Specific CD8+ T Cell Responses Abstract Number: 1524
Presenter: Carolyne Smith, PhD
About SQZ Biotechnologies
SQZ Biotechnologies is a clinical-stage biotechnology company
developing transformative cell therapies for patients with cancer,
infectious diseases, and other serious conditions. Using its
proprietary Cell Squeeze® technology, SQZ Biotechnologies offers
the unique ability to deliver multiple materials into many patient
cell types to engineer what we believe can be an unprecedented
range of potential therapeutics for a variety of diseases. SQZ
Biotechnologies has the potential to create well-tolerated cell
therapies that can provide therapeutic benefit for patients and to
improve the patient experience over existing cell therapy
approaches. With accelerated production timelines under 24 hours
and the opportunity to eliminate preconditioning and lengthy
hospital stays, our goal is to use the SQZ approach to establish a
new paradigm for cell therapies. Our first therapeutic applications
aim to leverage the potential to generate target-specific immune
responses, both in activation for the treatment of solid tumors and
infectious diseases and immune tolerance for the treatment of
unwanted immune reactions and autoimmune diseases. For more
information please visit www.sqzbiotech.com.
Forward Looking Statement
This press release may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained that do not relate to matters of
historical fact should be considered forward-looking statements,
including statements relating to upcoming events and presentations,
our product candidates, including the SQZ APC platform, preclinical
and clinical activities, clinical efficacy and therapeutic impact.
These forward-looking statements are based on management's current
expectations. Actual results could differ from those projected in
any forward-looking statements due to several risk factors. Such
factors include, among others, risks and uncertainties related to
the development of our product candidates, such as the SQZ APC
oncology pipeline, including our ongoing relationship with our
collaboration partners; the impact of the COVID-19 pandemic on our
operations and clinical activities; our need for additional funding
and our cash runway; the lengthy, expensive, and uncertain process
of clinical drug development, including uncertain outcomes of
clinical trials and potential delays in regulatory approval; our
ability to maintain our relationships with our third party vendors;
and protection of our proprietary technology, intellectual property
portfolio and the confidentiality of our trade secrets. These and
other important factors discussed under the caption "Risk Factors"
in our filings with the U.S. Securities and Exchange Commission
(SEC), as well as discussions of potential risks, uncertainties,
and other important factors in our subsequent filings with the SEC,
could cause actual results to differ materially from those
indicated by the forward-looking statements. Any forward-looking
statements represent management's estimates as of this date and SQZ
undertakes no duty to update this information, whether as a result
of new information, the occurrence of current events, or otherwise,
unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210310005202/en/
SQZ Biotechnologies IR: Rebecca Cohen Corporate and
Investor Relations rebecca.cohen@sqzbiotech.com 617-758-8672 ext.
728 Media: Kate Contreras kcontreras@w2ogroup.com
617-229-5960
SQZ Biotechnologies (NYSE:SQZ)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
SQZ Biotechnologies (NYSE:SQZ)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024